SPCC1223.01 Antibody

What is SPCC1223.09 and what cellular processes is it involved in?

SPCC1223.09 is a protein in Schizosaccharomyces pombe (fission yeast) with the UniProt number O74409 and Entrez Gene ID 2538957 . The protein is part of the cellular machinery in S. pombe, which serves as an important model organism for studying eukaryotic cellular processes. Fission yeast has been extensively used to investigate cell cycle regulation, chromosome dynamics, and DNA damage responses due to its similarity to higher eukaryotes in many fundamental cellular processes. When studying SPCC1223.09, researchers typically employ antibodies against this protein to elucidate its localization, expression levels, and interactions with other cellular components through techniques like Western blotting, immunoprecipitation, and immunofluorescence microscopy.

How should SPCC1223.09 antibodies be stored to maintain optimal activity?

SPCC1223.09 antibodies should be stored at -20°C or -80°C for long-term preservation of activity . For working aliquots, storage at 4°C is acceptable for short periods, but repeated freeze-thaw cycles should be avoided as they can lead to antibody degradation and reduced specificity. The antibody is typically shipped on blue ice to maintain its structural integrity during transit . When preparing working dilutions, it is advisable to use a suitable buffer that maintains protein stability, such as PBS with 0.1% sodium azide and 1% BSA. Always follow manufacturer-specific recommendations, as storage conditions may vary slightly depending on antibody formulation and purification method.

What validation methods should be used to confirm SPCC1223.09 antibody specificity?

Multiple validation approaches should be implemented to confirm antibody specificity:

• Positive and negative controls: Use the recombinant immunogen protein/peptide (provided with some commercial antibodies) as a positive control . For negative controls, use pre-immune serum or samples known not to express the target.

• Knockout/knockdown validation: Test the antibody on samples where SPCC1223.09 has been genetically deleted or suppressed.

• Western blot analysis: Confirm a single band of the expected molecular weight.

• Cross-reactivity testing: Examine potential cross-reactions with related proteins, especially when working with antibodies in species other than S. pombe.

• Peptide competition assay: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining.

Validation should be performed for each specific application (Western blot, immunoprecipitation, etc.) as antibody performance can vary between applications.

What are the optimal conditions for using SPCC1223.09 antibody in Western blotting?

For optimal Western blotting with SPCC1223.09 antibody, follow these methodological guidelines:

• Sample preparation: Extract proteins from S. pombe cells using a buffer containing protease inhibitors to prevent degradation.

• Protein separation: Use 10-12% SDS-PAGE gels for effective separation of proteins in the expected molecular weight range.

• Transfer conditions: Transfer to PVDF or nitrocellulose membranes at 100V for 1 hour or 30V overnight in cold transfer buffer.

• Blocking: Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute SPCC1223.09 antibody (typically 1:1000 to 1:5000) in blocking buffer and incubate overnight at 4°C .

• Washing and secondary antibody: Wash 3-5 times with TBST and incubate with anti-rabbit HRP-conjugated secondary antibody (since SPCC1223.09 antibody is rabbit-derived) .

• Detection: Use enhanced chemiluminescence detection reagents and expose to X-ray film or digital imaging system.

• Controls: Include positive control (recombinant protein) and pre-immune serum as negative control .

Optimization may be required for specific experimental conditions.

How can I optimize SPCC1223.09 antibody for use in ELISA applications?

For optimal ELISA applications with SPCC1223.09 antibody, consider the following methodological approach:

• Plate coating: Coat high-binding ELISA plates with target antigen (0.5-5 μg/mL) in carbonate buffer (pH 9.6) overnight at 4°C.

• Blocking: Block with 1-3% BSA in PBS or PBST for 1-2 hours at room temperature.

• Primary antibody titration: Perform a titration series (1:100 to 1:10,000) of SPCC1223.09 antibody to determine optimal concentration .

• Incubation conditions: Incubate primary antibody for 1-2 hours at room temperature or overnight at 4°C.

• Detection system: Use HRP-conjugated secondary antibody and TMB substrate for colorimetric detection.

• Validation controls:

  • Positive control: Recombinant SPCC1223.09 protein included with the antibody

  • Negative control: Pre-immune serum from the same rabbit

  • Background control: Wells without primary antibody

• Signal optimization: If signal is weak, consider extending incubation times, increasing antibody concentration, or using a more sensitive detection system.

What cross-reactivity concerns should be addressed when using SPCC1223.09 antibody?

When working with SPCC1223.09 antibody, consider these cross-reactivity issues:

• Species specificity: The antibody is specifically reactive to yeast species . When working with other organisms, thoroughly validate for potential cross-reactivity with homologous proteins.

• Pre-absorption testing: If cross-reactivity is suspected, perform pre-absorption tests with recombinant proteins of concern to determine specificity.

• Western blot analysis: Run samples from different species/cell types side by side to evaluate potential cross-reactivity patterns.

• Epitope conservation analysis: Perform bioinformatic analysis of the immunogen sequence to identify proteins with similar epitopes across species.

• Background reduction strategies:

  • Use higher dilutions of primary antibody

  • Pre-incubate antibody with non-specific proteins

  • Include blocking agents specific to your experimental system

  • Consider using monoclonal antibodies if polyclonal shows excessive cross-reactivity

• Knockout/knockdown controls: Use genetically modified samples lacking the target protein to confirm antibody specificity.

The polyclonal nature of the SPCC1223.09 antibody may increase the risk of cross-reactivity compared to monoclonal antibodies, requiring thorough validation .

How can SPCC1223.09 antibody be applied in protein-protein interaction studies?

For protein-protein interaction studies using SPCC1223.09 antibody, implement these methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Lyse S. pombe cells in a non-denaturing buffer

  • Pre-clear lysate with Protein A/G beads

  • Incubate cleared lysate with SPCC1223.09 antibody (2-5 μg)

  • Capture antibody-protein complexes with Protein A/G beads

  • Wash stringently to remove non-specific interactions

  • Elute and analyze by immunoblotting for potential interacting partners

• Proximity Ligation Assay (PLA):

  • Fix and permeabilize cells

  • Incubate with SPCC1223.09 antibody and antibody against potential interacting protein

  • Use species-specific PLA probes

  • Perform ligation and amplification

  • Visualize interaction spots by fluorescence microscopy

• Pull-down assays with recombinant protein:

  • Use the recombinant immunogen protein (provided with the antibody) as bait

  • Incubate with cell lysates

  • Analyze captured proteins by mass spectrometry

• Controls for validation:

  • Negative control: Pre-immune serum

  • Competition control: Pre-incubation with immunizing peptide

  • Reverse Co-IP: Immunoprecipitate with antibody against suspected interacting partner

This approach allows for identification and validation of proteins that physically interact with SPCC1223.09 in cellular contexts.

What considerations are important when comparing different antibody clones for detecting SPCC1223.09?

When comparing different antibodies for SPCC1223.09 detection, consider these critical factors:

• Epitope recognition: Different antibodies may recognize distinct epitopes on SPCC1223.09, affecting detection efficiency under various experimental conditions. Map the epitope recognition regions when possible.

• Performance comparison protocol:

  • Test all antibodies simultaneously under identical conditions

  • Use multiple techniques (Western blot, ELISA, immunofluorescence)

  • Quantify sensitivity and specificity for each method

  • Assess batch-to-batch consistency

• Antibody format considerations:

  • Polyclonal vs. monoclonal: The SPCC1223.09 antibody described is polyclonal , which offers broader epitope recognition but potentially more variability than monoclonal alternatives

  • Host species: Consider secondary antibody compatibility in your experimental system

  • Conjugation options: Evaluate whether direct conjugates might reduce background

• Validation stringency: Apply more rigorous validation methods for critical experiments:

  • Parallel testing with recombinant protein standards

  • Knockout/knockdown validation

  • Peptide competition assays

• Data analysis framework: Create a standardized scoring system for:

  • Signal-to-noise ratio

  • Specificity (single vs. multiple bands)

  • Reproducibility across experiments

  • Detection threshold

This approach is similar to methods used for comparing PD-L1 antibody clones, where different clones (such as SP142 and 22C3) showed significant differences in detection sensitivity and staining patterns .

How can SPCC1223.09 antibody be adapted for super-resolution microscopy applications?

For adapting SPCC1223.09 antibody for super-resolution microscopy:

• Antibody conjugation strategies:

  • Direct conjugation with small fluorophores (Alexa Fluor 647, Atto 488)

  • Use of minimally sized secondary detection systems (Fab fragments, nanobodies)

  • Enzymatic antibody fragmentation to reduce size and increase penetration

• Sample preparation optimization:

  • Test multiple fixation protocols (paraformaldehyde, methanol, glutaraldehyde)

  • Evaluate permeabilization agents (Triton X-100, saponin, digitonin)

  • Optimize blocking conditions to reduce non-specific binding

  • Consider tissue clearing techniques for complex samples

• Technical considerations for different super-resolution methods:

  • STORM/PALM: Ensure photoswitchable fluorophores and appropriate buffer systems

  • STED: Use fluorophores with high photostability

  • SIM: Focus on signal-to-noise ratio optimization

• Validation approach:

  • Correlative imaging with conventional microscopy

  • Co-localization with known interacting partners

  • Comparison with live-cell imaging when possible

• Controls and quantification:

  • Use pre-immune serum as negative control

  • Include samples with known expression patterns

  • Employ quantitative analysis of distribution and clustering

This methodological framework allows researchers to visualize SPCC1223.09 localization at nanoscale resolution, revealing potential novel insights about its subcellular distribution and co-localization patterns.

What are common causes of false positives or negatives when using SPCC1223.09 antibody?

Common sources of false results with SPCC1223.09 antibody include:

False Positives:

• Cross-reactivity with related proteins: Especially relevant when using polyclonal antibodies like SPCC1223.09 antibody . Conduct careful specificity testing with recombinant proteins or knockout controls.

• Non-specific binding: Can occur due to:

  • Insufficient blocking

  • Too high antibody concentration

  • Suboptimal washing conditions

  • Sample degradation with exposed epitopes

• Detection system artifacts:

  • HRP substrate precipitation

  • Endogenous peroxidase activity

  • Endogenous biotin when using avidin-biotin systems

False Negatives:

• Epitope masking: Occurs when:

  • Fixation destroys or masks the epitope

  • Post-translational modifications alter recognition

  • Protein-protein interactions block the epitope

• Technical issues:

  • Antibody degradation from improper storage (avoid repeated freeze-thaw cycles)

  • Insufficient incubation time

  • Wrong secondary antibody selection

  • Buffer incompatibility

• Sample preparation problems:

  • Protein degradation

  • Inefficient extraction

  • Unsuitable detergents

Methodological controls to implement:

• Include positive controls using recombinant protein

• Use pre-immune serum as negative control

• Perform peptide competition assays

• Implement concentration gradients to identify optimal antibody dilution

Similar validation challenges have been documented in other antibody systems, such as the PD-L1 detection where different antibody clones showed significantly different staining patterns and sensitivities .

How can I perform quantitative analysis of SPCC1223.09 expression in yeast samples?

For quantitative analysis of SPCC1223.09 expression:

• Western blot quantification:

  • Use a standard curve with recombinant SPCC1223.09 protein (provided with the antibody)

  • Include loading controls (actin, GAPDH)

  • Prepare serial dilutions of samples to ensure linearity of signal

  • Use digital imaging systems with appropriate dynamic range

  • Analyze with software like ImageJ, normalizing to loading controls

• ELISA-based quantification:

  • Develop a sandwich ELISA using capture and detection antibodies

  • Create standard curves with recombinant protein

  • Ensure sample matrix compatibility

  • Validate with spike-recovery experiments

• Flow cytometry analysis:

  • Permeabilize fixed cells for intracellular staining

  • Use directly conjugated antibody or minimally labeling secondary system

  • Include isotype controls

  • Quantify using mean fluorescence intensity

  • Calibrate with beads of known antibody binding capacity

• Real-time quantification strategies:

  • Correlate protein levels with mRNA expression

  • Consider whether post-translational modifications affect detection

  • Account for subcellular localization changes

• Statistical analysis:

  • Perform at least three biological replicates

  • Use appropriate statistical tests based on data distribution

  • Report confidence intervals and p-values

  • Consider Bland-Altman plots for method comparison

Implement appropriate normalization procedures based on cell number, total protein, or reference proteins to ensure accurate quantification across samples.

How should I validate SPCC1223.09 antibody for use with different sample preparation methods?

When validating SPCC1223.09 antibody across different sample preparation methods:

• Method comparison framework:

  • Test multiple extraction buffers (RIPA, NP-40, Triton X-100)

  • Compare different fixation methods (formaldehyde, methanol, acetone)

  • Evaluate various antigen retrieval techniques

  • Assess multiple blocking agents (BSA, casein, normal serum)

• Validation experiment design:

  • Process identical samples with different methods in parallel

  • Include recombinant protein control with each method

  • Test a dilution series of antibody for each preparation method

  • Include pre-immune serum controls

• Evaluation criteria:

  • Signal intensity

  • Signal-to-noise ratio

  • Specificity (single band vs. multiple bands)

  • Reproducibility across replicates

  • Detection of expected subcellular localization

• Documentation and standardization:

  • Create a detailed protocol for each validated method

  • Document the performance characteristics for each method

  • Establish acceptance criteria for future experiments

This rigorous validation approach ensures reproducible results across different experimental conditions and sample preparation methods.

How does antibody validation for SPCC1223.09 compare with validation of clinical antibodies like PD-L1 antibodies?

Antibody validation approaches for SPCC1223.09 share fundamental principles with clinical antibodies but differ in several important aspects:

• Stringency and regulatory requirements:

  • Clinical antibodies like PD-L1 (SP142, 22C3) undergo FDA/EMA approval processes

  • SPCC1223.09 antibody validation is typically laboratory-specific without regulatory oversight

  • Clinical antibodies require concordance studies across laboratories and platforms

• Validation methodology comparison:

  • Both require epitope specificity confirmation

  • Clinical antibodies undergo extensive cohort testing (e.g., SP142 vs 22C3 comparison across NSCLC patients)

  • SPCC1223.09 validation typically relies on recombinant protein controls and pre-immune serum

• Quantification standards:

  • Clinical antibodies employ standardized scoring systems (e.g., tumor proportion score)

  • Research antibodies like SPCC1223.09 often use relative quantification methods

  • Clinical antibodies establish specific cutoff values (≥1%, ≥5%, ≥50%) for decision-making

• Cross-platform validation:

  • PD-L1 antibodies require validation across multiple IHC platforms (Dako, Ventana)

  • Research antibodies typically validated on fewer platforms

  • Clinical antibodies are tested with different detection systems

• Consequence of false results:

  • Clinical antibodies: direct impact on patient treatment decisions

  • Research antibodies: primarily scientific integrity concerns

The differences in PD-L1 detection between SP142 and 22C3 antibodies (39.6% vs 66.7% positivity at ≥5% expression) illustrate how different antibodies against the same target can yield significantly different results, highlighting the importance of standardized validation.

What can researchers learn from antibody structure-function relationships when optimizing SPCC1223.09 antibody protocols?

Understanding antibody structure-function relationships can significantly enhance SPCC1223.09 antibody protocol optimization:

• Epitope-paratope interactions:

  • Antibodies contain variable regions with complementarity-determining regions (CDRs) that form the antigen-binding site

  • The SPCC1223.09 antibody is generated against recombinant protein , likely containing multiple epitopes

  • Sample preparation conditions that denature proteins may disrupt conformational epitopes

  • Consider whether your protocol might expose or mask epitopes

• Antibody class considerations:

  • SPCC1223.09 antibody is a polyclonal IgG

  • Understand the impact of different IgG subclasses on:

    • Protein A/G binding efficiency during purification

    • Complement activation

    • Fc receptor interactions that might cause background

• Structural insights for protocol optimization:

  • Antibody hinge region flexibility influences antigen binding

  • Temperature and pH affect antibody conformation and binding kinetics

  • Divalent cations can impact antibody-antigen interactions

  • Buffer components should preserve antibody structure

• Antibody fragment applications:

  • Consider using F(ab')2 or Fab fragments to reduce non-specific binding

  • Understand the trade-off between reduced avidity and improved tissue penetration

  • Enzymatic digestion conditions must be optimized to maintain antigen recognition

• Molecular weight considerations:

  • Full antibodies are approximately 150 kDa , which affects penetration in tissues

  • The large size may impact protocols like immunoelectron microscopy

  • Size considerations are critical for techniques like proximity ligation assays

This fundamental understanding of antibody structure provides a scientific basis for rational optimization of SPCC1223.09 antibody protocols rather than empirical trial-and-error approaches.

How can insights from comparing different PD-L1 antibody clones guide SPCC1223.09 antibody research design?

Lessons from comparative PD-L1 antibody studies provide valuable insights for SPCC1223.09 antibody research:

• Clone-dependent sensitivity differences:

  • PD-L1 detection varied significantly between SP142 and 22C3 antibodies (22.9% vs 45.8% at ≥50% cutoff)

  • Implies that different SPCC1223.09 antibody preparations might similarly vary in sensitivity

  • Recommendation: Test multiple antibody sources/lots for critical experiments

• Tissue-specific performance variation:

  • PD-L1 antibodies showed differential performance in squamous vs. non-squamous carcinomas

  • For SPCC1223.09: Different yeast growth conditions or genetic backgrounds might similarly affect detection

  • Recommendation: Validate antibody in each specific experimental context

• Standardized scoring systems:

  • PD-L1 testing employs defined cutoffs (≥1%, ≥5%, ≥50%)

  • Apply similar quantitative thresholds for SPCC1223.09 expression analysis

  • Recommendation: Develop standardized scoring methods appropriate for your experimental question

• Technical platform considerations:

  • PD-L1 antibodies performed differently on Dako vs. Ventana platforms

  • SPCC1223.09 detection might similarly vary between imaging systems, ELISA readers, etc.

  • Recommendation: Validate across all technical platforms to be used

• Impact of sample preparations:

  • PD-L1 detection varied between resected tissues and cellblocks

  • SPCC1223.09 detection may similarly vary with yeast sample preparation methods

  • Recommendation: Compare detection efficiency across all relevant sample types

This comparative approach provides a methodological framework for rigorous antibody validation in SPCC1223.09 research, improving experimental reliability and reproducibility.

What emerging technologies might enhance SPCC1223.09 antibody-based research?

Several emerging technologies hold promise for advancing SPCC1223.09 antibody applications:

• Single-cell antibody-based proteomics:

  • Mass cytometry (CyTOF) combining antibody specificity with mass spectrometry sensitivity

  • Microfluidic antibody capture for single-cell protein analysis

  • Single-cell Western blotting for heterogeneity assessment in yeast populations

  • Implementation would require metal-conjugated SPCC1223.09 antibodies

• Advanced imaging technologies:

  • Expansion microscopy for physically enlarging samples to improve resolution

  • Light-sheet microscopy for rapid 3D imaging with reduced photobleaching

  • Super-resolution techniques optimized for yeast cell architecture

  • These approaches could reveal novel SPCC1223.09 localization patterns

• Proximity-based interaction mapping:

  • BioID or TurboID for proximity-based biotinylation

  • APEX2 for electron microscopy-compatible proximity labeling

  • Application would require fusion proteins with SPCC1223.09 and validation with antibodies

• Antibody engineering approaches:

  • Nanobodies (single-domain antibodies) for improved penetration

  • Recombinant antibody fragments with site-specific conjugation

  • Bispecific antibodies for co-localization studies

  • These formats could overcome limitations of conventional SPCC1223.09 antibodies

• Multiplexed detection systems:

  • Cyclic immunofluorescence for sequential antibody staining/removal

  • DNA-barcoded antibodies for highly multiplexed detection

  • Mass spectrometry imaging with antibody-directed metal deposition

  • Would enable simultaneous analysis of SPCC1223.09 with multiple interacting partners

Implementation of these technologies would require careful validation comparable to that performed for clinical antibodies , with particular attention to specificity confirmation using the recombinant protein positive control .

How might synthetic antibody alternatives impact future SPCC1223.09 research?

Synthetic antibody alternatives present transformative opportunities for SPCC1223.09 research:

• Aptamer technology:

  • DNA/RNA aptamers selected against SPCC1223.09 protein

  • Advantages: chemical synthesis, thermal stability, site-specific modification

  • Challenges: potential reduced affinity, nuclease sensitivity

  • Research impact: Enable in vivo imaging and therapeutic targeting in model systems

• Designed ankyrin repeat proteins (DARPins):

  • Engineered binding proteins with high stability and specificity

  • Advantages: small size (~14-18 kDa vs. 150 kDa for antibodies ), high expression yield

  • Implementation pathway: Selection against purified SPCC1223.09 recombinant protein

  • Research impact: Superior tissue penetration for microscopy applications

• Affimers and monobodies:

  • Small non-antibody scaffolds with engineered binding sites

  • Advantages: production in bacterial systems, high stability

  • Applications: Improved pull-down assays, super-resolution microscopy

  • Validation approach: Direct comparison with conventional SPCC1223.09 antibody

• Synthetic antibody mimetics:

  • Computationally designed mimics of antibody paratopes

  • Advantages: rational design, customizable properties

  • Challenges: computational prediction accuracy

  • Research impact: Precisely targeted binding to specific SPCC1223.09 domains

• Comparative performance metrics:

The transition to synthetic alternatives would require thorough validation comparable to the approaches used for comparing antibody clones in clinical applications , ensuring that specificity and sensitivity are maintained or improved relative to conventional SPCC1223.09 antibody.

What research questions about SPCC1223.09 function remain unanswered due to current antibody limitations?

Several important research questions remain challenging due to current antibody limitations:

• Temporal dynamics of SPCC1223.09 expression and modification:

  • Current limitation: Antibodies provide static snapshots rather than dynamic information

  • Methodological need: Antibodies specific to post-translationally modified forms

  • Approach: Develop modification-specific antibodies or alternative live-cell reporters

  • Impact: Understanding regulatory mechanisms controlling SPCC1223.09 function

• Sub-organelle localization patterns:

  • Current limitation: Resolution constraints with conventional antibody detection

  • Methodological need: Super-resolution compatible antibody formats

  • Approach: Antibody fragmentation or alternative binding proteins with site-specific dyes

  • Impact: Precise mapping of SPCC1223.09 within complex structures

• Conformational states of SPCC1223.09:

  • Current limitation: Most antibodies cannot distinguish protein conformations

  • Methodological need: Conformation-specific antibodies or binding proteins

  • Approach: Selection strategies targeting specific structural states

  • Impact: Understanding structural basis of SPCC1223.09 function

• Low-abundance SPCC1223.09 interaction partners:

  • Current limitation: Background issues in immunoprecipitation with current antibodies

  • Methodological need: Higher specificity capture reagents

  • Approach: Advanced proximity labeling or crosslinking strategies

  • Impact: Comprehensive SPCC1223.09 interactome mapping

• Quantitative distribution across cellular compartments:

  • Current limitation: Challenges in quantitative immunofluorescence

  • Methodological need: Improved antibody labeling stoichiometry

  • Approach: Site-specific single-fluorophore labeling strategies

  • Impact: Mathematical modeling of SPCC1223.09 distributions